In a sign of strong demand, Genoptix priced its 5 million share offering at $17, above its proposed $14-$16 range. Genoptix provides specialized laboratory services to hematologists and oncologists and is in the enviable position of addressing a large and growing market where barriers to entry are relatively high. Lehman Brothers lead managed the IPO, and the stock is expected to commence trading on the NASDAQ under the ticker symbol "GXDX" on Tuesday. For more information about the company, view our Featured IPO write-up.
